losartan and Kidney Diseases studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

Excerpt	Relevance	Reference
" In the first stage, pentoxifylline decreased median proteinuria from 1,140 to 800 mg/g (median change, -23."	9.13	Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008)
"Losartan seemed to prevent an increase in proteinuria without altering the creatinine clearance level in patients with amyloidosis type AA during a 12-month period."	9.10	Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2002)
"Losartan therapy was associated with a marked and sustained reduction in proteinuria and in preservation of GFR in children with chronic proteinuric disorders."	9.10	Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. ( Ellis, D; Grosso, MJ; Janosky, JE; Moritz, ML; Reitz, S; Vats, A, 2003)
"Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK)."	8.87	[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. ( Kozlovskaia, LV; Milovanov, IuS; Milovanova, LIu, 2011)
" Unilateral ureteral obstruction (UUO) renal fibrosis model was established in mice by ligating the left ureter, and then randomly received losartan at a low dose (1 mg/kg) or a regular dose (3 mg/kg) for 2 weeks."	8.31	Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. ( Gu, W; Huang, Z; Li, P; Li, TS; Liu, G; Nie, H; Peng, YH; Xiao, J, 2023)
" We aimed to examine the preventive effect of an ARB, losartan, against bladder dysfunction due to aging-related severe hypertension."	8.12	Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. ( Higashi, Y; Karashima, T; Kurabayashi, A; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2022)
"In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)."	8.02	Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021)
" Losartan was efficient in preventing cells from undergoing further transdifferentiation, but this strategy was not sufficient to induce regression of the pre-existing tissue fibrosis."	7.81	Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015)
"To evaluate the effect of angiotensin receptor blocker (losartan) on renal function during and after relief of partial unilateral ureteral obstruction (PUO)."	7.76	Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan). ( Abol-Enein, H; Abou-Bieh, E; Barakat, N; Mosbah, A; Shokeir, AA; Soliman, SA; Wafa, EW, 2010)
"In animal models of hypertension, the efficacy of losartan is equivalent to the efficacy of ACE inhibitors."	7.69	Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. ( Broten, TP; Kivlighn, SD; Siegl, PK, 1995)
"Losartan is a typical Angiotensin II (ANG II) receptor antagonist and relaxes blood vessels."	5.72	Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. ( Ma, Y; Yu, R; Zhou, X; Zou, J, 2022)
"Proteinuria was diagnosed in 2003 (DPE 3."	5.35	[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008)
"Losartan treatment decreased the tissue expression of miR-21 and TGF-β and tissue fibrosis in kidney transplant patient, and it had a protective effect on allograft function and may delay chronic allograft dysfunction by reducing mediators of fibrosis."	5.27	Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers. ( Nafar, M; Samavat, S; Shahraki, E, 2018)
"A total of 439 hypertensive patients with metabolic syndrome and/or diabetes mellitus were randomized to 2 groups: group 1--ramipril (ACE-I) or perindopril and group 2--losartan (ARB)."	5.19	Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study). ( Soucek, M; Spinar, J; Vitovec, J, 2014)
"0] g/24 h proteinuria) were treated during 6-week periods with placebo, ARB (100 mg/d losartan), and ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide) combined with consecutively regular and low sodium diets (193 ± 62 versus 93 ± 52 mmol Na(+)/d)."	5.15	Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. ( Goldschmeding, R; Hemmelder, MH; Laverman, GD; Navis, G; Nguyen, TQ; Slagman, MC; Vogt, L; Waanders, F, 2011)
"Urinary KIM-1 level was increased in patients with nondiabetic CKD with proteinuria and decreased in parallel with proteinuria by using losartan, sodium restriction, their combination, losartan plus HCT, and the latter plus sodium restriction."	5.14	Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. ( Bonventre, JV; Damman, K; Hamming, I; Leuvenink, H; Navis, G; Vaidya, VS; van Goor, H; Vogt, L; Waanders, F, 2009)
"Aliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline CKD stage in patients with type 2 diabetes, hypertension, and nephropathy."	5.14	Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F; Rossing, P, 2010)
" In the first stage, pentoxifylline decreased median proteinuria from 1,140 to 800 mg/g (median change, -23."	5.13	Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008)
"Losartan therapy was associated with a marked and sustained reduction in proteinuria and in preservation of GFR in children with chronic proteinuric disorders."	5.10	Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. ( Ellis, D; Grosso, MJ; Janosky, JE; Moritz, ML; Reitz, S; Vats, A, 2003)
"Losartan seemed to prevent an increase in proteinuria without altering the creatinine clearance level in patients with amyloidosis type AA during a 12-month period."	5.10	Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2002)
"Losartan induced a drastic decrease in proteinuria accompanied by a reduction in urinary excretion of TGF-beta in patients with non-diabetic proteinuric renal diseases."	5.10	Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. ( Aguirre, R; Andrade, CF; Ara, JM; Arias, M; Bernis, C; Campistol, JM; Galceran, JM; Luño, J; Marín, R; Mora, J; Poveda, R; Praga, M; Prat, MV; Rivera, F, 2003)
"The objective of this study was to examine the effects of angiotensin II receptor blocker losartan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving and tubular function in hypertensive patients with non-diabetic nephropathy."	5.08	Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K, 1998)
"Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK)."	4.87	[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. ( Kozlovskaia, LV; Milovanov, IuS; Milovanova, LIu, 2011)
"Losartan is an effective antagonist of angiotensin II AT(1) receptors which has been shown to provide important clinical benefits in patients with hypertension, congestive heart failure and renal diseases."	4.87	Pharmacokinetic evaluation of losartan. ( Burnier, M; Wuerzner, G, 2011)
"This review describes recent clinical studies of eplerenone, a selective aldosterone blocker, in patients with hypertension."	4.81	Clinical implications of aldosterone blockade. ( Weber, MA, 2002)
" Unilateral ureteral obstruction (UUO) renal fibrosis model was established in mice by ligating the left ureter, and then randomly received losartan at a low dose (1 mg/kg) or a regular dose (3 mg/kg) for 2 weeks."	4.31	Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. ( Gu, W; Huang, Z; Li, P; Li, TS; Liu, G; Nie, H; Peng, YH; Xiao, J, 2023)
" We aimed to examine the preventive effect of an ARB, losartan, against bladder dysfunction due to aging-related severe hypertension."	4.12	Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. ( Higashi, Y; Karashima, T; Kurabayashi, A; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T, 2022)
"In the present study, we tested the hypothesis that there are significant sex differences in angiotensin II (Ang II)-induced hypertension and kidney injury using male and female wildtype (WT) and proximal tubule-specific AT1a receptor knockout mice (PT-Agtr1a-/-)."	4.02	Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. ( Alexander, B; Casarini, DE; Hassan, R; Leite, APO; Li, XC; Zheng, X; Zhuo, JL, 2021)
" Similar to losartan, Dojuksan ameliorated kidney inflammation and fibrosis in UUO mice."	4.02	Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk. ( Dorotea, D; Ha, H; Jiang, S; Kim, DS; Oh, DS; Son, E, 2021)
" Hypertension-induced marked elevation of renal malondialdehyde (MDA) and nitrite levels and reduction of reduced glutathione (GSH) level were inhibited by EGb761."	3.88	Protective effect of the standardized leaf extract of Ginkgo biloba (EGb761) against hypertension-induced renal injury in rats. ( Abd-Eldayem, AM; Abdel-Zaher, AO; El-Refaiy, AEM; Farghaly, HSM, 2018)
"To investigate the function of nephrin in podocytes and its relation to proteinuria in kidney diseases, and to study more clearly theoretical basis for the molecular mechanism of losartan anti-proteinuria and the special beneficial effects of losartan on podocyte injury."	3.83	Role of nephrin in podocyte injury induced by angiotension II. ( Yu, S, 2016)
" Losartan was efficient in preventing cells from undergoing further transdifferentiation, but this strategy was not sufficient to induce regression of the pre-existing tissue fibrosis."	3.81	Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. ( Arnoni, CP; Boim, MA; Maquigussa, E; Passos, CS; Pereira, LG, 2015)
"To evaluate the effect of angiotensin receptor blocker (losartan) on renal function during and after relief of partial unilateral ureteral obstruction (PUO)."	3.76	Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan). ( Abol-Enein, H; Abou-Bieh, E; Barakat, N; Mosbah, A; Shokeir, AA; Soliman, SA; Wafa, EW, 2010)
"Despite discontinuation of losartan over the subsequent six months, ARB pre-treatment completely prevented proteinuria and hypertension in these slow renal ablation rats."	3.74	Angiotensin II receptor blockade blocker pre-treatment largely prevents injury from gradual renal ablation in rats. ( Jeong, HJ; Kim, KH; Kim, Y; Mauer, M; Park, HW; Rozen, S; Shin, MH, 2007)
" Na and Cr excretions were decreased, while proteinuria and plasma ET-1 levels were normalized by losartan treatment, suggesting that renin-angiotensin system activation may have a role in leptin induced renal changes."	3.73	Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats. ( Akgun, H; Dursun, N; Gunduz, Z; Koc, N; Okur, H; Ozturk, F, 2005)
"Our data show that the effects of losartan and amlodipine on the absolute mean reduction of blood pressure and proteinuria in non-diabetic nephropathy patients are similar between the different ACE or AGT genotypes."	3.73	[Pharmacogenetics of angiotensin system in non diabetic nephropathy]. ( Alvarez, V; Arias, M; Campistol, JM; Coto, E; Fernández Andrade, C; Galcerán, JM; Luño, J; Marín, R; Poveda, R; Praga, M; Rivera, F; Vallés, M, 2005)
" We examined the effect of an angiotensin II receptor inhibitor (AT(1)) losartan, independent from its effects on blood pressure, on nitric oxide synthase (NOS) isoforms and cyclooxygenase-2 (COX-2) expression and the significance of this interaction on interstitial fibrosis in UUO."	3.72	Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. ( Carrizo, L; Manucha, W; Oliveros, L; Seltzer, A; Vallés, P, 2004)
"Angiotensin II (Ang II) has been shown to be implicated in the development of renal fibrosis in several forms of chronic glomerulonephritides, but the precise mechanisms of its effects remain unclear."	3.70	Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. ( Cerullo, G; Colucci, M; Gesualdo, L; Grandaliano, G; Monno, R; Ranieri, E; Rossiello, MR; Schena, FP; Semeraro, N; Ursi, M, 1999)
"In animal models of hypertension, the efficacy of losartan is equivalent to the efficacy of ACE inhibitors."	3.69	Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. ( Broten, TP; Kivlighn, SD; Siegl, PK, 1995)
"To study the effects of blockade of the renin-angiotensin system upon the development of hypertension, end-organ damage and mortality in Dahl salt-sensitive (DSS) rats using an angiotensin II receptor antagonist, losartan."	3.68	Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. ( Camargo, MJ; Campbell, WG; Laragh, JH; Mueller, FB; Sealey, JE; Timmermans, PB; von Lutterotti, N, 1992)
"In Japanese patients with type 2 diabetes and nephropathy, losartan offers renal protection and is generally well tolerated."	2.72	Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. ( Chan, JC; Cooper, ME; Keane, WF; Kurokawa, K; Shahinfar, S; Zhang, Z, 2006)
"Losartan was used in 45 consecutive hypertensive children with chronic renal parenchymal disorders and mean glomerular filtration rate (GFR) 99."	2.71	Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. ( Ellis, D; Janosky, JE; Moritz, ML; Vats, A, 2004)
"Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease."	2.43	Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006)
"Losartan was the first drug in this class to become commercially available."	2.40	Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. ( Burrell, LM; Johnston, CI, 1997)
"Losartan is a typical Angiotensin II (ANG II) receptor antagonist and relaxes blood vessels."	1.72	Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. ( Ma, Y; Yu, R; Zhou, X; Zou, J, 2022)
" Activation of the renin-angiotensin system (RAS) and associated inflammations may exacerbate the toxic effects of tacrolimus."	1.62	Evaluation of the Effect of Captopril and Losartan on Tacrolimus-induced Nephrotoxicity in Rats. ( Abeyat, H; Behmanesh, MA; Poormoosavi, SM; Sangtarash, E, 2021)
"Treatment with losartan or spironolactone alone significantly reduced various CKD-associated features."	1.56	Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats. ( Aggarwal, D; Singh, G, 2020)
"Calcitriol has important effects on cellular differentiation and proliferation, as well as on the regulation of the renin gene."	1.46	Calcitriol reduces kidney development disorders in rats provoked by losartan administration during lactation. ( Coimbra, TM; Costa, RS; da Silva, CGA; de Almeida, LF; Francescato, HDC, 2017)
"Losartan treatment also abrogated fibro-inflammatory disease, assessed by markers at the protein and messenger level."	1.39	Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging. ( Declèves, AE; Rychak, JJ; Sharma, K; Smith, DJ, 2013)
"Captopril treatment significantly reduced protein abundance of ACE, ANG II, AT1R and TGF-β."	1.39	Renin angiotensin system blockade ameliorates lead nephropathy. ( Chiou, TT; Hsu, CY; Huang, PC; Lee, CT; Lee, YT; Ng, HY; Tain, YL, 2013)
"AKF-PD was used to treat renal fibrosis in unilateral ureteral obstruction (UUO) obstructive nephropathy in rats."	1.39	Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. ( Cheng, GJ; Hu, GY; Huang, L; Mei, WJ; Peng, ZZ; Qin, J; Tao, LJ; Xie, YY; Yuan, QJ; Yuan, XN, 2013)
"Losartan treatment reduced the fibrosis in the CC UUO kidneys."	1.38	Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. ( Brazin, JA; Chen, J; Estephan, R; Felsen, D; Kameue, T; Maack, T; Mora, R; O'Connor, N; Poppas, DP; Reid, AC; Seshan, SV; Silver, RB; Veerappan, A, 2012)
"While proteinuria was reduced in all four of these patients by 45, 96, 53, and 64%, respectively, three patients experienced side effects requiring changes in the aliskiren dose."	1.37	Are we ready to use aliskiren in children? ( Filler, G; Kelland, EE; McAuley, LM, 2011)
"Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats."	1.37	Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. ( Cervenka, L; Chábová, VC; Hammock, BD; Honetschlägerová, Z; Husková, Z; Hwang, SH; Imig, JD; Kopkan, L; Kramer, HJ; Kujal, P; Sporková, A; Tesař, V; Vernerová, Z, 2011)
"Proteinuria was diagnosed in 2003 (DPE 3."	1.35	[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008)
"Losartan has protective effects against CDDP-induced nephrotoxicity as evidenced by restoration of normal serum levels of creatinine and BUN, and LDH leakage."	1.35	Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. ( Ain-Shoka, AA; El-Demerdash, E; Khalef, MM; Saleh, S, 2009)
"Late losartan treatment had no effect on any of the parameters in either kidney, and PD-123319 had no effect on either kidney."	1.34	Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat. ( Burt, LE; Chevalier, RL; Coleman, CM; Forbes, MS; Minor, JJ; Thornhill, BA, 2007)
"The current case indicates that late recurrences of scleroderma renal crisis are possible in renal transplant recipients and that angiotensin-converting enzyme inhibitors, rather than angiotensin II receptor blockers, may be the superior drugs for such patients."	1.33	Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. ( Cheung, WY; Gibson, IW; Jeffery, J; Karpinski, M; Rush, D, 2005)
"Aldosterone plays a key role in the pathogenesis of Ang II-induced organ damage."	1.33	Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. ( Al-Saadi, N; Dechend, R; Fiebeler, A; Hilfenhaus, G; Jeng, AY; Luft, FC; Maser-Gluth, C; Meiners, S; Muller, DN; Nussberger, J; Rong, S; Shagdarsuren, E; Webb, RL; Wellner, M, 2005)
"Reduction of proteinuria is a prerequisite for successful long-term renoprotection."	1.31	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. ( Andersen, S; Bos, H; De Jong, PE; De Zeeuw, D; Navis, G; Parving, HH; Rossing, P, 2000)
"Proteinuria was markedly reduced in both strains by L."	1.29	Losartan protects the rat kidney from ischemic injury. ( Cervenka, L; Heller, J; Hellerová, S; Kramer, HJ, 1996)

Research

Studies (159)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Glomerular Volume

Number of Participants With Decline in GFR

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	22 (13.84)	18.2507
2000's	73 (45.91)	29.6817
2010's	55 (34.59)	24.3611
2020's	9 (5.66)	2.80

Authors	Studies
Avdeef, A	1
Tam, KY	1
Shimizu, S	1
Nagao, Y	1
Kurabayashi, A	1
Shimizu, T	1
Higashi, Y	1
Karashima, T	1
Saito, M	1
Erichsen, L	1
Thimm, C	1
Bohndorf, M	1
Rahman, MS	1
Wruck, W	1
Adjaye, J	1
Zou, J	1
Zhou, X	3
Ma, Y	1
Yu, R	1
Orentas, M	1
Patel, N	1
Rodby, R	1
Hassan, S	1
Huang, Z	1
Nie, H	1
Liu, G	1
Li, P	1
Peng, YH	1
Xiao, J	1
Gu, W	1
Li, TS	1
Aggarwal, D	1
Singh, G	1
Jiang, S	1
Oh, DS	1
Dorotea, D	1
Son, E	1
Kim, DS	1
Ha, H	1
Poormoosavi, SM	1
Behmanesh, MA	1
Abeyat, H	1
Sangtarash, E	1
Leite, APO	1
Li, XC	1
Hassan, R	1
Zheng, X	1
Alexander, B	1
Casarini, DE	2
Zhuo, JL	1
Hosseinian, S	2
Rad, AK	1
Bideskan, AE	1
Soukhtanloo, M	2
Sadeghnia, H	1
Shafei, MN	2
Motejadded, F	1
Mohebbati, R	1
Shahraki, S	2
Beheshti, F	1
Zhao, Y	1
Wu, J	1
Zhang, M	1
Zhou, M	1
Xu, F	1
Zhu, X	1
Lang, Y	1
Yang, F	1
Yun, S	1
Shi, S	1
Liu, Z	1
de Almeida, LF	1
Francescato, HDC	1
da Silva, CGA	1
Costa, RS	1
Coimbra, TM	1
Abdel-Zaher, AO	1
Farghaly, HSM	1
El-Refaiy, AEM	1
Abd-Eldayem, AM	1
Roy, S	1
Rai, P	2
Eiymo Mwa Mpollo, MS	1
Chang, KH	1
Rizvi, T	1
Shanmukhappa, SK	1
VandenHeuvel, K	1
Aronow, B	1
Inagami, T	1
Cancelas, JA	1
Malik, P	1
Ebrahimzadeh Bideskan, A	1
Sadeghnia, HR	1
Samadi Noshahr, Z	1
Khajavi Rad, A	1
Nafar, M	1
Samavat, S	1
Shahraki, E	1
Silveira, KD	1
Barroso, LC	1
Vieira, AT	1
Cisalpino, D	1
Lima, CX	1
Bader, M	1
Arantes, RM	1
Dos Santos, RA	1
Simões-E-Silva, AC	1
Teixeira, MM	1
Qin, J	1
Xie, YY	1
Huang, L	1
Yuan, QJ	1
Mei, WJ	1
Yuan, XN	1
Hu, GY	1
Cheng, GJ	1
Tao, LJ	1
Peng, ZZ	1
Ng, HY	1
Tain, YL	1
Lee, YT	1
Hsu, CY	1
Chiou, TT	1
Huang, PC	1
Lee, CT	1
Spinar, J	1
Vitovec, J	1
Soucek, M	1
Declèves, AE	1
Rychak, JJ	1
Smith, DJ	1
Sharma, K	1
Smink, PA	1
Miao, Y	1
Eijkemans, MJ	1
Bakker, SJ	1
Raz, I	1
Parving, HH	3
Hoekman, J	1
Grobbee, DE	1
de Zeeuw, D	2
Lambers Heerspink, HJ	1
Arnoni, CP	1
Maquigussa, E	1
Passos, CS	1
Pereira, LG	1
Boim, MA	1
Lederman, R	1
Haque, S	1
Rehman, S	1
Kumar, V	1
Sataranatrajan, K	1
Malhotra, A	1
Kasinath, BS	1
Singhal, PC	1
Seifi, B	1
Kadkhodaee, M	1
Bakhshi, E	1
Ranjbaran, M	1
Zahmatkesh, M	1
Sedaghat, Z	1
Ahghari, P	1
Esmaeili, P	1
Yu, S	2
Sahin, I	1
Ozkaynak, B	1
Sar, M	1
Biter, HI	1
Mert, B	1
Okuyan, E	1
Kayalar, N	1
Can, MM	1
Güngör, B	1
Erentug, V	1
Dinckal, MH	1
Ren, Q	1
Wu, W	1
Mohapatra, A	1
Matthai, SM	1
Vijayakumar, K	1
Basu, G	1
Peña, C	1
Hernández-Fonseca, JP	1
Pedreañez, A	1
Viera, N	1
Mosquera, J	1
Dai, Q	1
Zhang, PQ	1
Wang, XQ	1
Nie, LF	1
Fu, XJ	1
Peng, W	2
Wang, Y	4
Li, J	1
Bi, YP	1
Mi, XH	1
Yuan, M	1
He, LQ	1
Kim, JH	1
Lee, YH	1
Lim, BJ	1
Jeong, HJ	2
Kim, PK	1
Shin, JI	1
Fang, J	1
Wang, W	1
Sun, S	1
Li, Q	2
Lu, X	1
Qiu, M	1
Zhang, Y	2
Tanamas, SK	1
Saulnier, PJ	1
Fufaa, GD	1
Wheelock, KM	1
Weil, EJ	1
Hanson, RL	1
Knowler, WC	1
Bennett, PH	1
Nelson, RG	1
Kim, H	1
Baek, CH	1
Lee, RB	1
Chang, JW	1
Yang, WS	1
Lee, SK	1
Lin, SL	1
Chen, YM	1
Chiang, WC	1
Wu, KD	1
Tsai, TJ	1
Siegl, PK	1
Kivlighn, SD	1
Broten, TP	1
Deng, A	1
Tang, T	1
Singh, P	1
Wang, C	1
Satriano, J	1
Thomson, SC	1
Blantz, RC	1
Waanders, F	3
Vaidya, VS	1
van Goor, H	1
Leuvenink, H	1
Damman, K	1
Hamming, I	1
Bonventre, JV	1
Vogt, L	3
Navis, G	3
Renke, M	1
Rutkowski, P	1
Tylicki, L	1
Zietkiewicz, M	1
Larczyński, W	1
Rutkowski, B	1
Mihailovic-Stanojevic, N	1
Jovovic, D	1
Miloradovic, Z	1
Grujic-Milanovic, J	1
Jerkic, M	1
Markovic-Lipkovski, J	1
Tang, TF	1
Zhou, QL	1
Zhu, LL	1
Tang, R	1
Ao, X	1
Perico, N	2
Cattaneo, D	1
Remuzzi, G	4
Krikken, JA	1
Dallinga-Thie, GM	1
Dikkeschei, LD	1
Navis, GJ	1
Dullaart, RP	1
Gersak, K	1
Cvijic, M	1
Cerar, LK	1
Zoja, C	1
Corna, D	1
Rottoli, D	1
Gaspari, F	1
Haskell, L	1
Abe, M	2
Okada, K	2
Maruyama, T	2
Matsumoto, K	2
Zuo, Y	2
Yancey, P	1
Castro, I	1
Khan, WN	1
Khan, W	1
Motojima, M	1
Ichikawa, I	1
Fogo, AB	3
Linton, MF	1
Fazio, S	1
Kon, V	2
Soliman, SA	1
Shokeir, AA	1
Mosbah, A	1
Abol-Enein, H	1
Barakat, N	1
Abou-Bieh, E	1
Wafa, EW	1
Saleh, S	1
Ain-Shoka, AA	1
El-Demerdash, E	1
Khalef, MM	1
Naito, T	1
Ma, LJ	2
Yang, H	1
Tang, Y	1
Han, JY	1
Helle, F	1
Iversen, BM	1
Chatziantoniou, C	2
Dilauro, M	1
Zimpelmann, J	1
Robertson, SJ	1
Genest, D	1
Burns, KD	1
Kong, J	1
Deb, DK	1
Chang, A	1
Li, YC	1
Suzuki, H	3
Takenaka, T	1
Thornton, SN	1
Fujihara, CK	4
Vieira, JM	1
Sena, CR	1
Ventura, BH	1
Malheiros, DM	5
Zatz, R	4
Persson, F	1
Lewis, JB	1
Lewis, EJ	1
Rossing, P	2
Hollenberg, NK	1
Okano, Y	1
Toya, Y	1
Azuma, K	1
Yabana, M	1
Tamura, K	1
Umemura, S	1
Landgraf, SS	1
Wengert, M	1
Silva, JS	1
Zapata-Sudo, G	1
Sudo, RT	1
Takiya, CM	1
Pinheiro, AA	1
Caruso-Neves, C	1
Beloborodova, AV	1
Morozova, TE	1
Shilov, EM	1
Kelland, EE	1
McAuley, LM	1
Filler, G	1
Burnier, M	1
Wuerzner, G	1
Heeba, GH	1
Kong, X	1
Zhang, DY	1
Wu, HB	1
Li, FX	1
Park, HW	2
Kim, Y	2
Kim, KH	2
Rozen, S	2
Najafian, B	1
Mauer, M	2
Fanelli, C	1
Fernandes, BH	1
Machado, FG	1
Okabe, C	1
Honetschlägerová, Z	1
Sporková, A	1
Kopkan, L	1
Husková, Z	1
Hwang, SH	1
Hammock, BD	1
Imig, JD	1
Kramer, HJ	2
Kujal, P	1
Vernerová, Z	1
Chábová, VC	1
Tesař, V	1
Cervenka, L	2
Slagman, MC	1
Nguyen, TQ	1
Hemmelder, MH	1
Laverman, GD	1
Goldschmeding, R	1
Milovanov, IuS	1
Kozlovskaia, LV	1
Milovanova, LIu	1
Veerappan, A	1
Reid, AC	1
O'Connor, N	1
Mora, R	1
Brazin, JA	1
Estephan, R	1
Kameue, T	1
Chen, J	1
Felsen, D	1
Seshan, SV	1
Poppas, DP	1
Maack, T	1
Silver, RB	1
Fu, W	1
Wang, H	1
Liang, Y	1
Yao, W	1
Chen, W	1
Ying, PH	1
Shi, X	1
Álvarez-Prats, A	1
Hernández-Perera, O	1
Díaz-Herrera, P	1
Ucero, ÁC	1
Anabitarte-Prieto, A	1
Losada-Cabrera, A	1
Ortiz, A	1
Rodríguez-Pérez, JC	1
Guerrot, D	1
Dussaule, JC	1
Mael-Ainin, M	1
Xu-Dubois, YC	1
Rondeau, E	1
Placier, S	1
Bocanegra, V	1
Rinaldi Tosi, M	1
Gil Lorenzo, A	1
Cacciamani, V	1
Manucha, W	2
Fornés, M	1
Vallés, PG	1
Haghighi, M	1
Nematbakhsh, M	2
Talebi, A	2
Nasri, H	2
Ashrafi, F	2
Roshanaei, K	1
Eshraghi-Jazi, F	1
Pezeshki, Z	2
Safari, T	2
Khazaei, M	1
Baradaran-Mahdavi, MM	1
Jafapisheh, A	1
Olia, B	1
Pirhaji, O	1
Hashemi-Nia, SJ	1
Eshraghi, F	1
Mortazavi, M	1
Shihab, FS	1
Bennett, WM	2
Isaac, J	1
Yi, H	1
Andoh, TF	2
Bertram, D	1
Blanc-Brunat, N	1
Sassard, J	1
Lo, M	1
Eguchi, K	1
Kario, K	1
Shimada, K	1
Weber, MA	1
Nakao, N	2
Yoshimura, A	2
Morita, H	2
Takada, M	1
Kayano, T	1
Ideura, T	2
Yang, CW	2
Ahn, HJ	1
Kim, WY	1
Li, C	2
Jung, JY	1
Yoon, SA	1
Kim, YS	2
Cha, JH	2
Kim, J	2
Bang, BK	1
Hasegawa, T	1
Minamoto, T	1
Oda, Y	1
Inui, K	1
Tayama, H	1
Nakamoto, Y	1
Dilek, K	1
Usta, M	1
Ersoy, A	1
Ozdemir, B	1
Yavuz, M	1
Güllülü, M	1
Yurtkuran, M	1
Tsutani, H	1
Takagi, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678]	Phase 3	170 participants (Actual)	Interventional	1995-08-31	Completed
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293]		125 participants (Anticipated)	Observational	2021-05-19	Recruiting
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria[NCT00097955]	Phase 2	496 participants	Interventional	2004-10-31	Completed
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease[NCT02875886]	Phase 4	28 participants (Actual)	Interventional	2016-09-30	Completed
A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors [NCT00140985]	Phase 4	97 participants (Actual)	Interventional	2000-02-29	Completed
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658]	Phase 3	90 participants (Anticipated)	Interventional	2017-08-01	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	*10^6 cubic microns (Mean)
Normoalbuminuria Losartan	5.4
Normoalbuminuria Placebo	5.6
Microalbuminuria Losartan	6.4
Microalbuminuria Placebo	7.0

Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

Intervention	participants (Number)
Normoalbuminuria Losartan	2
Normoalbuminuria Placebo	2
Microalbuminuria Losartan	1
Microalbuminuria Placebo	4

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

HbA1C Levels

Intervention	percentage (Mean)
Insulin Glargine, Metformin, Exenatide	-2.43
Insulin Glargine, Metformin, Prandial Insulin	0.44

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Number of Participants With Hypoglycemia

Intervention	% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide	7.1
Insulin Glargine, Metformin, Prandial Insulin	7.2

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

Weight Change During Trial

Intervention	Participants (Count of Participants)
Insulin Glargine, Metformin, Exenatide	0
Insulin Glargine, Metformin, Prandial Insulin	0

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

Article	Year
The association between adult-onset Still's disease and collapsing glomerulopathy: a case report. Journal of medical case reports, 2022, Oct-14, Volume: 16, Issue:1 Topics: Adolescent; Adult; Cyclosporine; Female; Fever; Humans; Kidney Diseases; Kidney Failure, Chronic; Lo	2022
[Recent clinical evidences of RAS inhibitors on chronic kidney diseases]. Nihon Jinzo Gakkai shi, 2010, Volume: 52, Issue:2 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimida	2010
Pharmacokinetic evaluation of losartan. Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Heart Failure; H	2011
[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. Terapevticheskii arkhiv, 2011, Volume: 83, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Calcitriol; Cardiovascular Diseases; Chronic Disease; Ergoc	2011
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers;	2002
Clinical implications of aldosterone blockade. American heart journal, 2002, Volume: 144, Issue:5 Suppl Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinica	2002
[Typing of hypouricemia (uric acid clearance)]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 1 Topics: Allopurinol; Creatinine; Humans; Inappropriate ADH Syndrome; Kidney Diseases; Kidney Tubules; Losart	2003
[Therapy for hypertension associated with kidney disease]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Feb-10, Volume: 92, Issue:2 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;	2003
Uric acid: role in cardiovascular disease and effects of losartan. Current medical research and opinion, 2004, Volume: 20, Issue:3 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hyperuri	2004
[Organ protection by angiotensin II receptor blockers]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals;	2004
Angiotensin type 1 receptor blockers in chronic kidney disease. Contributions to nephrology, 2004, Volume: 143 Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Clinical Trials as Topic; Diabetic Nephrop	2004
[The renin-angiotensin-aldosterone system -- more complex as previously thought]. Medizinische Klinik (Munich, Germany : 1983), 2005, Aug-15, Volume: 100, Issue:8 Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym	2005
Time to abandon microalbuminuria? Kidney international, 2006, Volume: 70, Issue:7 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers;	2006
[Antagonists of angiotensin II receptor]. Postepy higieny i medycyny doswiadczalnej, 1996, Volume: 50, Issue:1 Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Diseases; Humans; Hypertension; Imidazol	1996
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy]. Klinicheskaia meditsina, 1996, Volume: 74, Issue:3 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun	1996
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs & aging, 1997, Volume: 10, Issue:6 Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi	1997
[Role of the renin-angiotensin system in cardiovascular and renal diseases]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1997, Volume: 109, Issue:5 Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseas	1997
Angiotensin II receptor blockers in hypertension and renal disease. Hospital practice (1995), 1998, Apr-15, Volume: 33, Issue:4 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Kidney Diseases; Lo	1998
Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal disease? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1999, Volume: 14, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;	1999
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications. Postgraduate medicine, 2001, Volume: 109, Issue:4 Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitor	2001
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications. The Canadian journal of cardiology, 2002, Volume: 18 Suppl A Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;	2002

Article	Year
Downregulation of Profibrotic Gene Expression by Angiotensin Receptor Blockers. Iranian journal of kidney diseases, 2018, Volume: 12, Issue:6 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Down-Regulation; Female; Fi	2018
Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study). Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2014, Volume: 158, Issue:3 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block	2014
[Treatment of Proteinuria in Chronic Glomerular Disease Patients with Pi-Shen Deficiency Complicated Damp-Heat Syndrome by Yishen Qingre Huashi Recipe: a Clinical Study]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2015, Volume: 35, Issue:9 Topics: Blood Urea Nitrogen; Drugs, Chinese Herbal; Hot Temperature; Humans; Kidney Diseases; Kidney Glomeru	2015
Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial. Diabetes care, 2016, Volume: 39, Issue:11 Topics: Adult; Albumins; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression;	2016
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Chemokine CCL2;	2008
Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:1 Topics: Acetylglucosaminidase; Adult; Aged; Antihypertensive Agents; Biomarkers; Chronic Disease; Combined M	2009
Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin. Expert opinion on therapeutic targets, 2009, Volume: 13, Issue:5 Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cholesterol Ester Transfer Protei	2009
Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease. International journal of clinical pharmacology and therapeutics, 2009, Volume: 47, Issue:8 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2009
Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease. Pharmacotherapy, 2009, Volume: 29, Issue:9 Topics: Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Creatinine; Dose-Response Relationsh	2009
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes care, 2010, Volume: 33, Issue:11 Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Creatinine; Diabetes Mellitus, Type 2; Diabetic	2010
[An experience of the use of angiotensin II receptor blocker losartan in patients with metabolic syndrome and chronic kidney disease]. Kardiologiia, 2010, Volume: 50, Issue:8 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Blood Pressure	2010
Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chronic Disease; Combined Modality Therapy; Con	2011
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet (London, England), 2003, Jan-11, Volume: 361, Issue:9352 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Press	2003
Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis. Scandinavian journal of urology and nephrology, 2002, Volume: 36, Issue:6 Topics: Adult; Amyloidosis; Angiotensin Receptor Antagonists; Creatinine; Female; Humans; Kidney; Kidney Dis	2002
Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. American journal of physiology. Renal physiology, 2003, Volume: 284, Issue:5 Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Cross-Over Studies; Diuretics; Double	2003
Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: insights into mechanism. Clinical nephrology, 2003, Volume: 60, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Disease Progr	2003
Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. The Journal of pediatrics, 2003, Volume: 143, Issue:1 Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Child, Preschool; Creatinine; Dose-Respo	2003
Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003, Volume: 18, Issue:9 Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blocke	2003
Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy. Transplant international : official journal of the European Society for Organ Transplantation, 2004, Volume: 17, Issue:9 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Humans; Kidney; Kidney Dise	2004
Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. American journal of hypertension, 2004, Volume: 17, Issue:10 Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Child;	2004
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clinical and experimental nephrology, 2006, Volume: 10, Issue:3 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Creatinine;	2006
Palatability of angiotensin II antagonists among nephropathic children. British journal of clinical pharmacology, 2007, Volume: 63, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Bipheny	2007
Antiproteinuric effect of Losartan in patients with chronic renal diseases. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997, Volume: 12, Issue:1 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug	1997
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1998, Volume: 13, Issue:12 Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Ove	1998
Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension. Journal of human hypertension, 2000, Volume: 14, Issue:5 Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Circulation; B	2000
A comparative study of losartan and enalapril on erythropoiesis and renal function in hypertensive patients with renal parenchymal disease. Clinical nephrology, 2000, Volume: 54, Issue:5 Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2000

Article	Year
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological	2010
Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats. European journal of pharmacology, 2022, May-05, Volume: 922 Topics: Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr	2022
Activation of the Renin-Angiotensin System Disrupts the Cytoskeletal Architecture of Human Urine-Derived Podocytes. Cells, 2022, 03-24, Volume: 11, Issue:7 Topics: Angiotensin II; Humans; Kidney; Kidney Diseases; Losartan; Podocytes; Renin-Angiotensin System	2022
Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 149 Topics: Animals; Fibrosis; Kidney; Kidney Diseases; Losartan; Male; Metabolic Networks and Pathways; Mice; M	2022
Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. Archives of biochemistry and biophysics, 2023, 10-15, Volume: 748 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Epithelial Cell	2023
Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:4 Topics: Animals; Catalase; Cytokines; Glutathione; Kidney; Kidney Diseases; Losartan; Male; Rats, Wistar; Re	2020
Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 80 Topics: Animals; Cell Line; Collagen Type I; Drugs, Chinese Herbal; Fibronectins; Fibrosis; Kidney Diseases;	2021
Evaluation of the Effect of Captopril and Losartan on Tacrolimus-induced Nephrotoxicity in Rats. Drug research, 2021, Volume: 71, Issue:5 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Conve	2021
Sex differences in angiotensin II-induced hypertension and kidney injury: role of AT1a receptors in the proximal tubule of the kidney. Clinical science (London, England : 1979), 2021, 08-13, Volume: 135, Issue:15 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial	2021
Thymoquinone ameliorates renal damage in unilateral ureteral obstruction in rats. Pharmacological reports : PR, 2017, Volume: 69, Issue:4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzoquinones; Biomarkers; Captopr	2017
Angiotensin II induces calcium/calcineurin signaling and podocyte injury by downregulating microRNA-30 family members. Journal of molecular medicine (Berlin, Germany), 2017, Volume: 95, Issue:8 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Calcium; Calcium Sign	2017
Calcitriol reduces kidney development disorders in rats provoked by losartan administration during lactation. Scientific reports, 2017, 09-13, Volume: 7, Issue:1 Topics: Animals; Biomarkers; Biopsy; Blood Pressure; Body Weight; Breast Feeding; Calcitriol; Chemokine CCL2	2017
Protective effect of the standardized leaf extract of Ginkgo biloba (EGb761) against hypertension-induced renal injury in rats. Clinical and experimental hypertension (New York, N.Y. : 1993), 2018, Volume: 40, Issue:8 Topics: Animals; Antihypertensive Agents; Arterial Pressure; Cardiovascular Agents; Ginkgo biloba; Glutathio	2018
Angiotensin receptor signaling in sickle cell anemia has a reno-protective effect on urine concentrating ability but results in sickle glomerulopathy. American journal of hematology, 2018, Volume: 93, Issue:7 Topics: Adult; Anemia, Sickle Cell; Angiotensin II Type 1 Receptor Blockers; Animals; Captopril; Child; Dise	2018
Nigella sativa extract is a potent therapeutic agent for renal inflammation, apoptosis, and oxidative stress in a rat model of unilateral ureteral obstruction. Phytotherapy research : PTR, 2018, Volume: 32, Issue:11 Topics: Angiotensin II; Animals; Apoptosis; Captopril; Chemokine CCL2; Creatinine; Fibrosis; Inflammation; K	2018
Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy. PloS one, 2013, Volume: 8, Issue:6 Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Doxorubicin	2013
Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. Nephrology (Carlton, Vic.), 2013, Volume: 18, Issue:10 Topics: Angiotensin II; Animals; Antioxidants; Cell Line; Class Ia Phosphatidylinositol 3-Kinase; Collagen T	2013
Renin angiotensin system blockade ameliorates lead nephropathy. Biochemical and biophysical research communications, 2013, Aug-23, Volume: 438, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A	2013
Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging. American journal of physiology. Renal physiology, 2013, Nov-01, Volume: 305, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Diet, High-Fat; Disease Models, Animal	2013
The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:2 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitu	2014
Inhibition of cellular transdifferentiation by losartan minimizes but does not reverse type 2 diabetes-induced renal fibrosis. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:3 Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cell Movement; Cell Transdifferentiation; Chole	2015
Renin angiotensin system modulates mTOR pathway through AT2R in HIVAN. Experimental and molecular pathology, 2014, Volume: 96, Issue:3 Topics: AIDS-Associated Nephropathy; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2	2014
Angiotensin II in paraventricular nucleus contributes to sympathoexcitation in renal ischemia-reperfusion injury by AT1 receptor and oxidative stress. The Journal of surgical research, 2015, Volume: 193, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Blood Pressure; Cycl	2015
Role of nephrin in podocyte injury induced by angiotension II. Journal of receptor and signal transduction research, 2016, Volume: 36, Issue:1 Topics: Angiotensin II; Anti-Arrhythmia Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cul	2016
Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model. European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:19 Topics: Animals; Contrast Media; Disease Models, Animal; Drug Therapy, Combination; Ergocalciferols; Kidney	2014
Effects of losartan on expression of monocyte chemoattractant protein-1 (MCP-1) in hyperuricemic nephropathy rats. Journal of receptor and signal transduction research, 2015, Volume: 35, Issue:5 Topics: Animals; Chemokine CCL2; Dose-Response Relationship, Drug; Hyperuricemia; Kidney; Kidney Diseases; L	2015
Quiz page: an unusual cause of nephrotic syndrome. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 66, Issue:1 Topics: Antihypertensive Agents; Collagen Diseases; Collagen Type III; Edema; Fibrosis; Humans; Hypertension	2015
Renal oxidative stress and renal CD8(+) T-cell infiltration in mercuric chloride-induced nephropathy in rats: role of angiotensin II. Journal of immunotoxicology, 2016, Volume: 13, Issue:3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A	2016
Influence of cyclosporine A on glomerular growth and the effect of mizoribine and losartan on cyclosporine nephrotoxicity in young rats. Scientific reports, 2016, Mar-07, Volume: 6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Histocytochemistry; Kidney; Kidney D	2016
Metabolomics study of renal fibrosis and intervention effects of total aglycone extracts of Scutellaria baicalensis in unilateral ureteral obstruction rats. Journal of ethnopharmacology, 2016, Nov-04, Volume: 192 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Discr	2016
Anti-Fibrotic Effect of Losartan, an Angiotensin II Receptor Blocker, Is Mediated through Inhibition of ER Stress via Up-Regulation of SIRT1, Followed by Induction of HO-1 and Thioredoxin. International journal of molecular sciences, 2017, Jan-31, Volume: 18, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Disease Models, Ani	2017
Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1995, Volume: 13, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr	1995
Regulation of oxygen utilization by angiotensin II in chronic kidney disease. Kidney international, 2009, Volume: 75, Issue:2 Topics: Angiotensin II; Animals; Captopril; Disease Models, Animal; Kidney Diseases; Losartan; Nitric Oxide	2009
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. Przeglad lekarski, 2008, Volume: 65, Issue:6 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type	2008
Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antineoplastic Agents; Bl	2009
[Effects of fosinopril and losartan on the expression of Toll- like receptor 4 in renal tubular epithelia cells]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2008, Volume: 33, Issue:10 Topics: Animals; Cell Line; Epithelial Cells; Fosinopril; Hypertension; Kidney Diseases; Kidney Tubules; Los	2008
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:1 Topics: Animals; Antihypertensive Agents; Biomarkers; Chronic Disease; Disease Models, Animal; Disease Progr	2009
Angiotensin II receptor blockers in pregnancy: a report of five cases. Reproductive toxicology (Elmsford, N.Y.), 2009, Volume: 28, Issue:1 Topics: Abnormalities, Drug-Induced; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe	2009
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney international, 2009, Volume: 76, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antidiur	2009
Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Ca	2009
Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan). Urology, 2010, Volume: 75, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chronic Disease; Dogs; Kidney Diseases; Losartan;	2010
Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy, 2009, Volume: 55, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Blood Urea Nitrogen; Cispla	2009
Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An	2010
Losartan increases NO release in afferent arterioles during regression of L-NAME-induced renal damage. American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterioles; Blood Pressur	2010
Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:6 Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con	2010
Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:6 Topics: Angiotensin I; Animals; Cells, Cultured; Chemokine CCL2; Collagen Type I; Connective Tissue Growth F	2010
RAAS blockade in combination with diuretic therapy increases urine excretion, which in turn increases drinking and thus reduces erythropoietin and proteinuria. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:7 Topics: Chronic Disease; Diuretics; Drinking Behavior; Drug Therapy, Combination; Erythropoietin; Hemodiluti	2010
Early brief treatment with losartan plus mycophenolate mofetil provides lasting renoprotection in a renal ablation model. American journal of nephrology, 2010, Volume: 32, Issue:2 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Press	2010
[Effects of combination therapy with losartan/hydrochlorothiazide on the relationships between base blood pressure, autonomic function, and health-related QOL]. Nihon Jinzo Gakkai shi, 2010, Volume: 52, Issue:7 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Autonomic Nervous System; Bl	2010
Changes in angiotensin receptors expression play a pivotal role in the renal damage observed in spontaneously hypertensive rats. American journal of physiology. Renal physiology, 2011, Volume: 300, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Collagen; Cyclic AMP-Dependent Protein	2011
Are we ready to use aliskiren in children? Pediatric nephrology (Berlin, Germany), 2011, Volume: 26, Issue:3 Topics: Adolescent; Age Factors; Amides; Angiotensin II Type 1 Receptor Blockers; Child, Preschool; Chronic	2011
Angiotensin II receptor blocker, losartan, ameliorates gentamicin-induced oxidative stress and nephrotoxicity in rats. Pharmacology, 2011, Volume: 87, Issue:3-4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Bacterial Agents; Antioxidants; Gentamicins;	2011
Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats. Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blotting, Western; DNA Primers; Enz	2011
Angiotensin II receptor blocker pretreatment of rats undergoing sudden renal ablation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Glomerular Filtration Rate; Hypertension; Kidney D	2012
Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation. American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Blood Pressure;	2011
Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. Journal of hypertension, 2011, Volume: 29, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cytochrome P-450 CYP1A1; Disease M	2011
Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. American journal of physiology. Renal physiology, 2012, Jan-01, Volume: 302, Issue:1 Topics: Angiotensin II; Animals; Cell Degranulation; Fibrosis; Humans; In Vitro Techniques; Kidney; Kidney D	2012
Renal microvascular injury in chronic aristolochic acid nephropathy and protective effects of Cozaar. Renal failure, 2012, Volume: 34, Issue:1 Topics: Animals; Aristolochic Acids; Chronic Disease; Kidney; Kidney Diseases; Losartan; Male; Microvessels;	2012
Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:7 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Blotting, Wester	2012
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PloS one, 2012, Volume: 7, Issue:3 Topics: Animals; Biomarkers; Blood Pressure; Cell Adhesion Molecules; Disease Progression; Gene Expression R	2012
Angiotensin AT(1) receptor inhibition-induced apoptosis by RhoA GTPase activation and pERK1/2 signaling pathways in neonatal obstructive nephropathy. Histology and histopathology, 2012, Volume: 27, Issue:7 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Apoptosis; Blotting, Western; Di	2012
The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences. Renal failure, 2012, Volume: 34, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Urea Nitrogen; Cisplatin; Creatinine; Female	2012
A combination of vitamin C and losartan for cisplatin-induced nephrotoxicity in rats. Iranian journal of kidney diseases, 2012, Volume: 6, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Ascorbic Acid; Biomarkers; Blood Pro	2012
Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity. Kidney international, 2002, Volume: 62, Issue:2 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cyclospo	2002
Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2002, Volume: 283, Issue:5 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure;	2002
Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation, 2003, Feb-15, Volume: 75, Issue:3 Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Body Weight; Chronic D	2003
Collagenofibrotic glomerulopathy with a widespread expression of type-V collagen. Virchows Archiv : an international journal of pathology, 2003, Volume: 442, Issue:2 Topics: Aged; Captopril; Collagen Type III; Collagen Type V; Female; Fluorescent Antibody Technique, Indirec	2003
The COOPERATE trial. Lancet (London, England), 2003, Mar-22, Volume: 361, Issue:9362 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dose-Response Relationship, Drug;	2003
The COOPERATE trial. Lancet (London, England), 2003, Mar-22, Volume: 361, Issue:9362 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Creatinine; Diuretics; Dose-Respo	2003
[Scleroderma renal crisis following withdrawal of therapy with losartan]. La Revue de medecine interne, 2003, Volume: 24, Issue:4 Topics: Acute Disease; Anti-Inflammatory Agents; Antihypertensive Agents; Causality; Female; Humans; Hyperte	2003
Cardiology patient page. Angiotensin receptor blockers. Circulation, 2003, Jun-24, Volume: 107, Issue:24 Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Bip	2003
Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. American journal of physiology. Renal physiology, 2004, Volume: 286, Issue:5 Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cyclooxyg	2004
Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. Kidney international, 2004, Volume: 65, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Cyclooxygenase 2; Female; Fibrosis;	2004
Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. Journal of the American Society of Nephrology : JASN, 2004, Volume: 15, Issue:7 Topics: Albumins; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Angiotensins; Animals; Antihype	2004
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:5 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert	2005
Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. American journal of physiology. Renal physiology, 2005, Volume: 289, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr	2005
Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:8 Topics: Angiotensin II; Apoptosis; Cells, Cultured; Culture Media, Conditioned; Dose-Response Relationship,	2005
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation, 2005, Jun-14, Volume: 111, Issue:23 Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Angiotensin II; Angiotensinogen; Animals; Animals, Genet	2005
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation, 2005, Jun-15, Volume: 79, Issue:11 Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; K	2005
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nature medicine, 2005, Volume: 11, Issue:8 Topics: ADAM Proteins; ADAM17 Protein; Angiotensin II; Animals; Blotting, Western; DNA Primers; ErbB Recepto	2005
Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats. Regulatory peptides, 2005, Dec-15, Volume: 132, Issue:1-3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Creatinine; Kidney; Kidney Disease	2005
[Pharmacogenetics of angiotensin system in non diabetic nephropathy]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25, Issue:4 Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel	2005
Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade. Clinical nephrology, 2005, Volume: 64, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Hemodynamics; H	2005
RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney international, 2006, Volume: 69, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen;	2006
Acute renal failure induced by an angiotensin II receptor antagonist in a 14-year-old boy with reflux nephropathy. Pediatric nephrology (Berlin, Germany), 2006, Volume: 21, Issue:4 Topics: Acute Kidney Injury; Adolescent; Angiotensin II Type 1 Receptor Blockers; Humans; Kidney Diseases; L	2006
[Kidney protection leads to heart protection, too]. MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34 Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive	2006
Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society. Clinical and experimental nephrology, 2006, Volume: 10, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabet	2006
Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:5 Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angio	2007
Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. American journal of physiology. Renal physiology, 2007, Volume: 292, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Diuretics	2007
[Losartan-induced Stevens-Johnson syndrome in a geriatric patient]. Ugeskrift for laeger, 2007, Mar-26, Volume: 169, Issue:13 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Humans; K	2007
Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat. American journal of physiology. Renal physiology, 2007, Volume: 293, Issue:1 Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin	2007
Angiotensin II receptor blockade blocker pre-treatment largely prevents injury from gradual renal ablation in rats. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2007, Volume: 8, Issue:3 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Drug Administration S	2007
Time-course reduction of renal function in rats on high sodium intake: acute reversal by potassium canrenoate. Clinical and experimental pharmacology & physiology, 2008, Volume: 35, Issue:4 Topics: Albuminuria; Animals; Blood Pressure; Canrenoic Acid; Dose-Response Relationship, Drug; Glomerular F	2008
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:8 Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors	2008
Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. The American journal of physiology, 1995, Volume: 269, Issue:4 Pt 2 Topics: Animals; Biphenyl Compounds; Blood Pressure; Cyclosporine; Enalapril; Furosemide; Hydralazine; Imida	1995
Upregulation of renin-angiotensin system and downregulation of kallikrein in obstructive nephropathy. The American journal of physiology, 1993, Volume: 264, Issue:5 Pt 2 Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Gene Expression; Imidazoles; Kallikrein	1993
Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney international, 1995, Volume: 48, Issue:4 Topics: Angiotensin II; Animals; Biphenyl Compounds; Gene Expression; Imidazoles; Immunohistochemistry; Kidn	1995
Renal impairment associated with losartan. Annals of internal medicine, 1996, Apr-15, Volume: 124, Issue:8 Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Female; Humans; Imidazoles; Kidney Diseases; Losa	1996
Losartan protects the rat kidney from ischemic injury. Kidney international. Supplement, 1996, Volume: 55 Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Hypertension; Imid	1996
Role of aldosterone in the remnant kidney model in the rat. The Journal of clinical investigation, 1996, Aug-15, Volume: 98, Issue:4 Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biph	1996
Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Clinical and experimental pharmacology & physiology. Supplement, 1995, Volume: 22, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Capt	1995
Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice. Japanese journal of pharmacology, 1997, Volume: 75, Issue:1 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An	1997
Antiproteinuric effect of losartan in patients with chronic renal diseases. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997, Volume: 12, Issue:10 Topics: Chronic Disease; Humans; Kidney Diseases; Losartan; Proteinuria	1997
Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. Journal of the American Society of Nephrology : JASN, 1998, Volume: 9, Issue:2 Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bl	1998
Hepatic injury associated with losartan. The Annals of pharmacotherapy, 1998, Volume: 32, Issue:12 Topics: Aged; Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Humans; Kidney Diseases; Losa	1998
Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney international, 1999, Volume: 56, Issue:2 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Anti-Bacterial Agents; Antihypertensive Agents; Bl	1999
Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney international. Supplement, 2000, Volume: 75 Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropa	2000
Renin-angiotensin system inhibitors as antihypertrophic agents. Die Pharmazie, 2000, Volume: 55, Issue:8 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals;	2000
Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney international, 2000, Volume: 58, Issue:6 Topics: Aging; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihypertensive Agents; Aorta, Thor	2000
Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent. Nephron, 2001, Volume: 87, Issue:1 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pr	2001
Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron, 2001, Volume: 88, Issue:3 Topics: Adult; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diure	2001
Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. Journal of hypertension, 1992, Volume: 10, Issue:9 Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Cerebrovascular Disorders; Hypertension	1992

losartan and Kidney Diseases